Genor Biopharma Holdings Limited (HK:6998)
:6998
Want to see HK:6998 full AI Analyst Report?
6998 Stock Chart & Stats
HK$3.06
HK$0.04(2.16%)
At close: 4:00 PM EST
HK$3.06
HK$0.04(2.16%)
Day’s Range― - ―
52-Week RangeHK$1.54 - HK$5.60
Previous CloseN/A
Volume193.50K
Average Volume (3M)909.38K
Market Cap
HK$3.35B
Enterprise ValueHK$1.24B
Total Cash (Recent Filing)HK$1.06B
Total Debt (Recent Filing)HK$1.49B
Price to Earnings (P/E)6.1
Beta0.48
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,011,213,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.17
Price to Sales (P/S)1.67
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Profitability And Cash GenerationThe sharp 2025 turn to profitability and positive free cash flow is a durable improvement in operating economics. Sustained margins and cash conversion support reinvestment in R&D and commercialization, reduce near-term reliance on external funding, and strengthen negotiating power with partners.
Manufacturing And CDMO CapabilityOwning large-scale biologics manufacturing and CDMO capabilities is a structural competitive advantage. It diversifies revenue beyond product sales, secures supply for biosimilars, improves gross margin control, and creates long-term customer relationships that underpin durable revenue streams.
Meaningful Equity Base And Moderate LeverageA sizable equity base and moderate reported leverage provide financial flexibility to fund clinical programs and commercial expansion without immediate solvency pressure. This cushion helps absorb R&D setbacks, supports capital-intensive biologics scale-up, and reduces default risk over time.
Bears Say
Revenue Volatility And Historical LossesThe company's revenue and profitability track record is inconsistent, with multiple years of losses and even zero revenue in some periods. Such volatility weakens confidence that the 2025 improvement is repeatable, complicates long-term planning, partner commitments, and predictable cash flows.
Rapid Increase In DebtA sharp rise in debt in a short period increases interest and refinancing burdens and raises leverage risk. If revenue or margins deteriorate, servicing elevated debt could force cost cuts or dilutive financing, limiting capacity to invest consistently in R&D and commercial execution over the medium term.
Historic Cash-Flow InstabilityAlthough 2025 shows positive operating and free cash flow, multiple prior years of negative cash generation indicate dependence on external financing historically. One-year cash improvement may reflect timing or one-off factors; persistent positive cash flow is needed to sustainably fund growth and limit refinancing risk.
Genor Biopharma Holdings Limited News
6998 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was HK$1.54 and its highest was HK$5.60 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is HK$3.35B.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 66 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Genor Biopharma Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.375 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.375.
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 2,011,213,700 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Genor Biopharma Holdings Limited reported an EPS of HK$0.375 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in HK:6998
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
Technical Analysis
Antengene Corporation Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―